In summary, we found that PARP inhibition in macrophages leads to a reprogramming of TAMs toward an anti-tumor, highly phagocytic phenotype that significantly contributes to the anti-tumor activity of olaparib. The gene discussed is PARP1; the disease is neoplasm.